| (+)-Licarin |
|
|
|
|
|
|
|
|
|
|
|
|
| (+)-Nortrachelogenin |
|
|
|
|
|
|
|
|
|
|
|
98.68% |
| (-)-Latifolin |
|
|
|
|
|
|
|
|
|
|
|
|
| (22S,23S)-Homobrassinolide |
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| (2S)-SB02024 |
|
|
|
|
|
|
|
|
|
|
|
98.14% |
| (3aS,4R,9bR)-G-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| (3R,10R,14aS)-AZD4625 |
|
|
|
|
|
|
|
|
|
|
|
98.00% |
| (R)-CCG-1423 |
|
|
|
|
|
|
|
|
|
|
|
|
| (R)-GSK-F1 |
|
|
|
|
|
|
|
|
|
|
|
|
| (R)-HM5023507 |
|
|
|
|
|
|
|
|
|
|
|
|
| (R)-IHMT-PI3Kδ-372 |
|
|
|
|
|
|
|
|
|
|
|
99.75% |
| (R)-PI3Kδ-IN-15 |
|
|
|
|
|
|
|
|
|
|
|
99.52% |
| (Rac)-AZD 6482 |
|
|
|
|
|
|
|
|
|
|
|
98.51% |
| (Rac)-AZD8186 |
|
|
|
|
|
|
|
|
|
|
|
|
| (S)-1-Boc-3-aminopiperidine |
|
|
|
|
|
|
|
|
|
|
|
99.76% |
| (S)-AZD 6482 |
|
|
|
|
|
|
|
|
|
|
|
|
| (S)-GSK-F1 |
|
|
|
|
|
|
|
|
|
|
|
98.01% |
| (S)-Phe-A110/B319 |
|
|
|
|
|
|
|
|
|
|
|
|
| (S)-PI3K-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
99.50% |
| (S)-PI3Kα-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| (S)-Tersolisib |
|
|
|
|
|
|
|
|
|
|
|
99.18% |
| (S)-Zovegalisib |
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| (±)-10-Gingerol |
|
|
|
|
|
|
|
|
|
|
|
|
| (±)-Armepavine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| 1,3,5-Tricaffeoylquinic acid |
|
|
|
|
|
|
|
|
|
|
|
|
| 1,3-Dicaffeoylquinic acid |
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| 1-Monopalmitin |
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| 1-Monopalmitin-d31 |
|
|
|
|
|
|
|
|
|
|
|
|
| 1-Deoxynojirimycin |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| 10-Gingerol |
|
|
|
|
|
|
|
|
|
|
|
99.48% |
| 17β-Hydroxywortmannin |
|
|
|
|
|
|
|
|
|
|
|
|
| 2,4-Dichlorothieno[3,2-d]pyrimidine |
|
|
|
|
|
|
|
|
|
|
|
|
| 20-5,14-HEDE |
|
|
|
|
|
|
|
|
|
|
|
98.34% |
| 20-5,14-HEDE-d2 |
|
|
|
|
|
|
|
|
|
|
|
|
| 20-5,14-HEDE-d2-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| 20-5,14-HEDE-d2-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| Alisol A 24-acetate |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| 25(R,S)-Ruscogenin |
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| 3-Methyladenine |
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| 3-Methyladenine-d3 |
|
|
|
|
|
|
|
|
|
|
|
98.98% |
| Desmethylglycitein |
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| 4′-Hydroxywogonin |
|
|
|
|
|
|
|
|
|
|
|
98.22% |
| 4,4'-Sulfonyldiphenol-d8 |
|
|
|
|
|
|
|
|
|
|
|
99.21% |
| 4-Vinylcyclohexene dioxide |
|
|
|
|
|
|
|
|
|
|
|
98.57% |
| 4-Methylbenzylidene camphor |
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| 5,4'-Dihydroxy-6,8-dimethoxy-7-O-rhamnosyl flavone |
|
|
|
|
|
|
|
|
|
|
|
|
| 6-O-Caffeoylarbutin |
|
|
|
|
|
|
|
|
|
|
|
99.47% |
| 6-O-Isobutyrylbritannilactone |
|
|
|
|
|
|
|
|
|
|
|
98.34% |
| 740 Y-P |
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| 740 Y-P TFA |
|
|
|
|
|
|
|
|
|
|
|
|
| 8-Gingerol |
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| 8-Prenylnaringenin |
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| 9(R)-PAHSA |
|
|
|
|
|
|
|
|
|
|
|
|
| 9-Methyl-β-carboline |
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| A2073 |
|
|
|
|
|
|
|
|
|
|
|
|
| A66 |
|
|
|
|
|
|
|
|
|
|
|
99.73% |
| Acalisib |
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| Acetyl-Exenatide |
|
|
|
|
|
|
|
|
|
|
|
|
| ALK/PI3K/AKT-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| Alpelisib |
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Alpelisib |
|
|
|
|
|
|
|
|
|
|
|
|
| Alpelisib hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.55% |
| alpha-Bisabolol |
|
|
|
|
|
|
|
|
|
|
|
80.0% |
| ALR2-IN-9 |
|
|
|
|
|
|
|
|
|
|
|
|
| AM-0687 |
|
|
|
|
|
|
|
|
|
|
|
|
| AM-1430 |
|
|
|
|
|
|
|
|
|
|
|
|
| AM-8508 |
|
|
|
|
|
|
|
|
|
|
|
|
| AM-9635 |
|
|
|
|
|
|
|
|
|
|
|
|
| Amdizalisib |
|
|
|
|
|
|
|
|
|
|
|
|
| AMG 511 |
|
|
|
|
|
|
|
|
|
|
|
99.76% |
| AMG319 |
|
|
|
|
|
|
|
|
|
|
|
99.09% |
| Antcin K |
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-CD146 Antibody (AA98) |
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-osteoporosis agent-4 |
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 137 |
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 164 |
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 190 |
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 235 |
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 271 |
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 273 |
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 319 |
|
|
|
|
|
|
|
|
|
|
|
|
| Antihypertensive agent 7 |
|
|
|
|
|
|
|
|
|
|
|
|
| Antiproliferative agent-57 |
|
|
|
|
|
|
|
|
|
|
|
|
| Antiproliferative agent-67 |
|
|
|
|
|
|
|
|
|
|
|
|
| Antitumor agent-86 |
|
|
|
|
|
|
|
|
|
|
|
|
| AP4-43 |
|
|
|
|
|
|
|
|
|
|
|
|
| Apitolisib |
|
|
|
|
|
|
|
|
|
|
|
99.29% |
| AQX-016A |
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| Arteanoflavone |
|
|
|
|
|
|
|
|
|
|
|
|
| AS-041164 |
|
|
|
|
|
|
|
|
|
|
|
99.02% |
| AS-604850 |
|
|
|
|
|
|
|
|
|
|
|
99.32% |
| AS-605240 |
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| AS-605240 potassium |
|
|
|
|
|
|
|
|
|
|
|
|
| AS2541019 |
|
|
|
|
|
|
|
|
|
|
|
|
| ATM Inhibitor-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| ATM Inhibitor-4 |
|
|
|
|
|
|
|
|
|
|
|
|
| ATR-IN-15 |
|
|
|
|
|
|
|
|
|
|
|
|
| Auriculasin |
|
|
|
|
|
|
|
|
|
|
|
98.54% |
| Autophinib |
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| AZD 6482 |
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| AZD-7648 |
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| AZD-7648 |
|
|
|
|
|
|
|
|
|
|
|
|
| AZD-8835 |
|
|
|
|
|
|
|
|
|
|
|
98.38% |
| AZD3458 |
|
|
|
|
|
|
|
|
|
|
|
99.71% |
| AZD4625 |
|
|
|
|
|
|
|
|
|
|
|
98.44% |
| AZD8154 |
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| AZD8186 |
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| Batiraxcept |
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| BAY1082439 |
|
|
|
|
|
|
|
|
|
|
|
99.35% |
| BBO-10203 |
|
|
|
|
|
|
|
|
|
|
|
99.12% |
| BGT226 |
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| BGT226 maleate |
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| BI-113823 |
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| Bimiralisib |
|
|
|
|
|
|
|
|
|
|
|
98.62% |
| BJ-2302 |
|
|
|
|
|
|
|
|
|
|
|
|
| Boc-L-cyclobutylglycine |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| BPH-628 |
|
|
|
|
|
|
|
|
|
|
|
|
| BrAC-GGFG-Aminal-PI3K/mTOR-IN-21 |
|
|
|
|
|
|
|
|
|
|
|
|
| Brevianamide F |
|
|
|
|
|
|
|
|
|
|
|
99.03% |
| BYBC-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| C-8 Ceramide-1-phosphate |
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| C-VGB3 |
|
|
|
|
|
|
|
|
|
|
|
|
| Cajanol |
|
|
|
|
|
|
|
|
|
|
|
|
| CAL-130 |
|
|
|
|
|
|
|
|
|
|
|
|
| CAL-130 Hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
98.74% |
| CAL-130 Racemate |
|
|
|
|
|
|
|
|
|
|
|
|
| Calebin A |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| CAY10505 |
|
|
|
|
|
|
|
|
|
|
|
98.70% |
| CAY10526 |
|
|
|
|
|
|
|
|
|
|
|
99.12% |
| CC-11 |
|
|
|
|
|
|
|
|
|
|
|
|
| CC-M-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| CDK8-IN-19 |
|
|
|
|
|
|
|
|
|
|
|
|
| CGS 15943 |
|
|
|
|
|
|
|
|
|
|
|
99.55% |
| CHF-6523 |
|
|
|
|
|
|
|
|
|
|
|
|
| CHMFL-PI3KD-317 |
|
|
|
|
|
|
|
|
|
|
|
98.04% |
| CHMFL-PI4K-127 |
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| CHNQD-01281 |
|
|
|
|
|
|
|
|
|
|
|
|
| CK37 |
|
|
|
|
|
|
|
|
|
|
|
|
| CKD-712 |
|
|
|
|
|
|
|
|
|
|
|
|
| CNX-1351 |
|
|
|
|
|
|
|
|
|
|
|
98.87% |
| COH-19 |
|
|
|
|
|
|
|
|
|
|
|
|
| Copanlisib-NH |
|
|
|
|
|
|
|
|
|
|
|
|
| COVA208 |
|
|
|
|
|
|
|
|
|
|
|
|
| COX-2/PI3K-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| COX-2/PI3K-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| CPL302-253 |
|
|
|
|
|
|
|
|
|
|
|
|
| Creatine monohydrate |
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| Creatine-13C monohydrate |
|
|
|
|
|
|
|
|
|
|
|
|
| CRI9 |
|
|
|
|
|
|
|
|
|
|
|
|
| CXJ-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| CZC24832 |
|
|
|
|
|
|
|
|
|
|
|
99.07% |
| D-106669 |
|
|
|
|
|
|
|
|
|
|
|
|
| D-87503 |
|
|
|
|
|
|
|
|
|
|
|
|
| D-Allose |
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| D-Allose-13C |
|
|
|
|
|
|
|
|
|
|
|
|
| D-Allose-13C-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| D-Allose-13C-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| D-GsMTx4 |
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| D-GsMTx4 TFA |
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| D-myo-Inositol-1,3,4,5,6-pentaphosphate sodium |
|
|
|
|
|
|
|
|
|
|
|
|
| D927 |
|
|
|
|
|
|
|
|
|
|
|
99.46% |
| Dactolisib |
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Dactolisib hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| Dactolisib Tosylate |
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| Daphnoretin |
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| DCZ3301 |
|
|
|
|
|
|
|
|
|
|
|
99.73% |
| Dehydroxy-oridonin-vinyl ester |
|
|
|
|
|
|
|
|
|
|
|
|
| Demethoxyviridiol |
|
|
|
|
|
|
|
|
|
|
|
|
| Desmethyl-VS-5584 |
|
|
|
|
|
|
|
|
|
|
|
|
| Desmethyl-VS-5584 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
98.63% |
| Dezapelisib |
|
|
|
|
|
|
|
|
|
|
|
|
| DFX117 |
|
|
|
|
|
|
|
|
|
|
|
|
| DHW-208 |
|
|
|
|
|
|
|
|
|
|
|
|
| DHW-221 |
|
|
|
|
|
|
|
|
|
|
|
|
| Diphenyl disulfide |
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Disitertide |
|
|
|
|
|
|
|
|
|
|
|
98.03% |
| Disitertide diammonium |
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| Disitertide TFA |
|
|
|
|
|
|
|
|
|
|
|
|
| DM-PIT-1 |
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Doxycycline calcium |
|
|
|
|
|
|
|
|
|
|
|
|
| Doxycycline hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| Doxycycline-13C,d3 |
|
|
|
|
|
|
|
|
|
|
|
|
| DS-7423 |
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| DS02312223 |
|
|
|
|
|
|
|
|
|
|
|
98.24% |
| Duvelisib |
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Duvelisib (R enantiomer) |
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| DZ2002 |
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Eganelisib |
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| EGCG Octaacetate |
|
|
|
|
|
|
|
|
|
|
|
98.57% |
| EGFR WT/T790M-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-182 |
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-192 |
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-196 |
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-213 |
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-214 |
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR/PI3Kα-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| Egg oil |
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| EpskA21 |
|
|
|
|
|
|
|
|
|
|
|
|
| ErbB2 peptide |
|
|
|
|
|
|
|
|
|
|
|
|
| Erucic acid sodium |
|
|
|
|
|
|
|
|
|
|
|
|
| Erufosine |
|
|
|
|
|
|
|
|
|
|
|
|
| ETP-45658 |
|
|
|
|
|
|
|
|
|
|
|
98.97% |
| ETP-46321 |
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| FAK-IN-22 |
|
|
|
|
|
|
|
|
|
|
|
|
| FAP-PI3KI1 |
|
|
|
|
|
|
|
|
|
|
|
|
| FASN-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
| FD2056 |
|
|
|
|
|
|
|
|
|
|
|
|
| FD2157 |
|
|
|
|
|
|
|
|
|
|
|
|
| FD223 |
|
|
|
|
|
|
|
|
|
|
|
98.05% |
| FD274 |
|
|
|
|
|
|
|
|
|
|
|
99.45% |
| Fenhexamid |
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| Fenhexamid-d10 |
|
|
|
|
|
|
|
|
|
|
|
|
| Fenitrothion-d6 |
|
|
|
|
|
|
|
|
|
|
|
|
| FHND5032 |
|
|
|
|
|
|
|
|
|
|
|
99.49% |
| Fimepinostat |
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Fimepinostat mesylate |
|
|
|
|
|
|
|
|
|
|
|
|
| FKL-137 |
|
|
|
|
|
|
|
|
|
|
|
|
| FLT3-IN-36 |
|
|
|
|
|
|
|
|
|
|
|
|
| FOXM1-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| FTI-277 |
|
|
|
|
|
|
|
|
|
|
|
|
| FTI-277 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
| Galloylpaeoniflorin |
|
|
|
|
|
|
|
|
|
|
|
98.30% |
| Gamma-glutamylcysteine ammonium |
|
|
|
|
|
|
|
|
|
|
|
|
| GDC-0326 |
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Gedatolisib |
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Gedatolisib-d6 |
|
|
|
|
|
|
|
|
|
|
|
|
| Gedatolisib-d8 |
|
|
|
|
|
|
|
|
|
|
|
|
| Ginsenoside F2 |
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Ginsenoside Rg4 |
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| GNE-293 |
|
|
|
|
|
|
|
|
|
|
|
|
| GNE-317 |
|
|
|
|
|
|
|
|
|
|
|
98.76% |
| GNE-477 |
|
|
|
|
|
|
|
|
|
|
|
98.75% |
| GNE-490 |
|
|
|
|
|
|
|
|
|
|
|
96.79% |
| GNE-493 |
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| GNE-493 (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
| GO-203 TFA |
|
|
|
|
|
|
|
|
|
|
|
98.39% |
| GP262 |
|
|
|
|
|
|
|
|
|
|
|
98.43% |
| GS-9901 |
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| GSK-F1 |
|
|
|
|
|
|
|
|
|
|
|
95.06% |
| GSK1059615 |
|
|
|
|
|
|
|
|
|
|
|
98.81% |
| GSK2292767 |
|
|
|
|
|
|
|
|
|
|
|
98.89% |
| GSK251 |
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| GSK2636771 |
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| GSK2636771 methyl |
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC-IN-43 |
|
|
|
|
|
|
|
|
|
|
|
|
| Hecubine |
|
|
|
|
|
|
|
|
|
|
|
|
| Hirsutenone |
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| Hit20 |
|
|
|
|
|
|
|
|
|
|
|
|
| HL-8 |
|
|
|
|
|
|
|
|
|
|
|
99.17% |
| HM5023507 |
|
|
|
|
|
|
|
|
|
|
|
|
| HS-173 |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| hSMG-1 inhibitor 11e |
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| hSMG-1 inhibitor 11j |
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| Hyaluronic acid (MW 50000-100000) |
|
|
|
|
|
|
|
|
|
|
|
|
| Hyaluronic acid sodium (MW 200-1560) |
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| Hyaluronic acid sodium (MW 800kDa) |
|
|
|
|
|
|
|
|
|
|
|
|
| Hyaluronic acid, low endotoxin |
|
|
|
|
|
|
|
|
|
|
|
|
| Hydroxyflutamide |
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| Hypoglycemic agent 3 |
|
|
|
|
|
|
|
|
|
|
|
|
| HYS-072 |
|
|
|
|
|
|
|
|
|
|
|
|
| HZX-02-059 |
|
|
|
|
|
|
|
|
|
|
|
99.40% |
| I194496 |
|
|
|
|
|
|
|
|
|
|
|
98.52% |
| IBL-302 |
|
|
|
|
|
|
|
|
|
|
|
95.49% |
| IC-87114 |
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Ifupinostat |
|
|
|
|
|
|
|
|
|
|
|
99.30% |
| IHMT-PI3K-315 |
|
|
|
|
|
|
|
|
|
|
|
|
| IHMT-PI3K-455 |
|
|
|
|
|
|
|
|
|
|
|
|
| IHMT-PI3Kδ-372 |
|
|
|
|
|
|
|
|
|
|
|
99.69% |
| IITZ-01 |
|
|
|
|
|
|
|
|
|
|
|
98.18% |
| IMC-EB10 |
|
|
|
|
|
|
|
|
|
|
|
98% |
| iMDK |
|
|
|
|
|
|
|
|
|
|
|
99.35% |
| iMDK quarterhydrate |
|
|
|
|
|
|
|
|
|
|
|
99.37% |
| IMM-H012 |
|
|
|
|
|
|
|
|
|
|
|
|
| Inavolisib |
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| IPI-3063 |
|
|
|
|
|
|
|
|
|
|
|
99.59% |
| Iridin |
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| Isocucurbitacin B |
|
|
|
|
|
|
|
|
|
|
|
98.98% |
| Isopsoralidin |
|
|
|
|
|
|
|
|
|
|
|
|
| Isorhamnetin-3-O-glucoside |
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Itacnosertib |
|
|
|
|
|
|
|
|
|
|
|
99.06% |
| Itacnosertib hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.43% |
| Izorlisib |
|
|
|
|
|
|
|
|
|
|
|
99.01% |
| JE-133 |
|
|
|
|
|
|
|
|
|
|
|
|
| JMC14 |
|
|
|
|
|
|
|
|
|
|
|
|
| JRN73958 |
|
|
|
|
|
|
|
|
|
|
|
|
| JZ19 |
|
|
|
|
|
|
|
|
|
|
|
|
| Kaempferol 3-neohesperidoside |
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| KIM-161 |
|
|
|
|
|
|
|
|
|
|
|
|
| KRAS IN-44 |
|
|
|
|
|
|
|
|
|
|
|
|
| KRAS-IN-55 |
|
|
|
|
|
|
|
|
|
|
|
|
| KRASG12C IN-16 |
|
|
|
|
|
|
|
|
|
|
|
|
| KS-133 |
|
|
|
|
|
|
|
|
|
|
|
98.75% |
| KTC1101 |
|
|
|
|
|
|
|
|
|
|
|
98.09% |
| KU-0060648 |
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| L-Borneol 7-O-[β-D-apiofuranosyl-(1→6)]-β-D-glucopyranoside |
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| LAS191954 |
|
|
|
|
|
|
|
|
|
|
|
|
| LAS195319 |
|
|
|
|
|
|
|
|
|
|
|
|
| LASSBio-2337 |
|
|
|
|
|
|
|
|
|
|
|
|
| LC-MG-10 |
|
|
|
|
|
|
|
|
|
|
|
|
| LCI40 |
|
|
|
|
|
|
|
|
|
|
|
|
| Leniolisib |
|
|
|
|
|
|
|
|
|
|
|
99.38% |
| Leniolisib phosphate |
|
|
|
|
|
|
|
|
|
|
|
98.88% |
| Leniolisib-d5 |
|
|
|
|
|
|
|
|
|
|
|
98.78% |
| Levomilnacipran |
|
|
|
|
|
|
|
|
|
|
|
|
| Levomilnacipran-d10 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| LIB3S0280 |
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Licoflavanone |
|
|
|
|
|
|
|
|
|
|
|
|
| Liensinine perchlorate |
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| Linperlisib |
|
|
|
|
|
|
|
|
|
|
|
98.83% |
| Loliolide |
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| LQEQ-19 (mouse, rat) |
|
|
|
|
|
|
|
|
|
|
|
|
| LT-1339-553 |
|
|
|
|
|
|
|
|
|
|
|
|
| LTURM 36 |
|
|
|
|
|
|
|
|
|
|
|
|
| Lupenone |
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| LX2343 |
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| LY294002 |
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| LY294002 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| M802 |
|
|
|
|
|
|
|
|
|
|
|
|
| MARY1 |
|
|
|
|
|
|
|
|
|
|
|
|
| MCX 28 |
|
|
|
|
|
|
|
|
|
|
|
|
| MDVN1003 |
|
|
|
|
|
|
|
|
|
|
|
|
| MEK/PI3K-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| MEK/PI3K-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| Melafolone |
|
|
|
|
|
|
|
|
|
|
|
|
| Methyl Eugenol |
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Methyllucidone |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| MIPS-21335 |
|
|
|
|
|
|
|
|
|
|
|
99.61% |
| MIPS-9922 |
|
|
|
|
|
|
|
|
|
|
|
99.25% |
| MJ04 |
|
|
|
|
|
|
|
|
|
|
|
98.08% |
| ML-220 |
|
|
|
|
|
|
|
|
|
|
|
|
| Molephantin |
|
|
|
|
|
|
|
|
|
|
|
|
| Momordicine I |
|
|
|
|
|
|
|
|
|
|
|
97.0% |
| MPT0L145 |
|
|
|
|
|
|
|
|
|
|
|
|
| MRS2768 tetrasodium salt |
|
|
|
|
|
|
|
|
|
|
|
98.7% |
| mTOR inhibitor-10 |
|
|
|
|
|
|
|
|
|
|
|
|
| mTOR inhibitor-13 |
|
|
|
|
|
|
|
|
|
|
|
|
| mTOR inhibitor-16 |
|
|
|
|
|
|
|
|
|
|
|
|
| mTOR inhibitor-17 |
|
|
|
|
|
|
|
|
|
|
|
|
| mTOR inhibitor-24 |
|
|
|
|
|
|
|
|
|
|
|
|
| mTOR inhibitor-25 |
|
|
|
|
|
|
|
|
|
|
|
|
| MTX-211 |
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| MTX-211 (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
| MTX-216 |
|
|
|
|
|
|
|
|
|
|
|
|
| MTX-241F |
|
|
|
|
|
|
|
|
|
|
|
|
| MTX-531 |
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| Multi-target kinase inhibitor 4 |
|
|
|
|
|
|
|
|
|
|
|
|
| Musk ketone |
|
|
|
|
|
|
|
|
|
|
|
99.21% |
| Myrislignan |
|
|
|
|
|
|
|
|
|
|
|
99.53% |
| Myrislignan-13C,d2 |
|
|
|
|
|
|
|
|
|
|
|
|
| Mytoxin B |
|
|
|
|
|
|
|
|
|
|
|
|
| N6-Cyclohexyladenosine |
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Naphthazarin |
|
|
|
|
|
|
|
|
|
|
|
99.59% |
| Nemiralisib |
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Nemiralisib hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| Nemiralisib succinate |
|
|
|
|
|
|
|
|
|
|
|
|
| NF-κB-IN-19 |
|
|
|
|
|
|
|
|
|
|
|
|
| NIBR-17 |
|
|
|
|
|
|
|
|
|
|
|
98.00% |
| Nic-15 |
|
|
|
|
|
|
|
|
|
|
|
|
| Nogo-B-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| NPS 2390 |
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| NSC781406 |
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| NVP-BAG956 |
|
|
|
|
|
|
|
|
|
|
|
99.21% |
| NVP-BBD130 |
|
|
|
|
|
|
|
|
|
|
|
|
| NVP-CLR457 |
|
|
|
|
|
|
|
|
|
|
|
|
| NVP-QAV-572 |
|
|
|
|
|
|
|
|
|
|
|
98.53% |
| NVS-PI3-4 |
|
|
|
|
|
|
|
|
|
|
|
99.40% |
| Oleanolic acid 28-O-β-D-glucopyranoside |
|
|
|
|
|
|
|
|
|
|
|
99.42% |
| Omipalisib |
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| OMS14 |
|
|
|
|
|
|
|
|
|
|
|
99.09% |
| ON 146040 |
|
|
|
|
|
|
|
|
|
|
|
95.05% |
| Orobol |
|
|
|
|
|
|
|
|
|
|
|
98.14% |
| Oroselol |
|
|
|
|
|
|
|
|
|
|
|
|
| Osthenol |
|
|
|
|
|
|
|
|
|
|
|
99.15% |
| Oxypeucedanin |
|
|
|
|
|
|
|
|
|
|
|
99.50% |
| P110δ-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
98.44% |
| Pabgraminone C |
|
|
|
|
|
|
|
|
|
|
|
|
| pan-KRAS-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
96.70% |
| Pan-RAS-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
| Panulisib |
|
|
|
|
|
|
|
|
|
|
|
|
| PARP/PI3K-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
99.40% |
| Parsaclisib |
|
|
|
|
|
|
|
|
|
|
|
99.71% |
| Parsaclisib hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.33% |
| Paxalisib |
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| PD-1/PD-L1-IN-54 |
|
|
|
|
|
|
|
|
|
|
|
|
| Pegloxenatide |
|
|
|
|
|
|
|
|
|
|
|
90.00% |
| Penetratin-PI3Kγ(126-150) |
|
|
|
|
|
|
|
|
|
|
|
|
| Pertuzumab-LD3 |
|
|
|
|
|
|
|
|
|
|
|
|
| Peruvoside |
|
|
|
|
|
|
|
|
|
|
|
99.32% |
| PF-04691502 |
|
|
|
|
|
|
|
|
|
|
|
99.33% |
| PF-04979064 |
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| PF-06465603 |
|
|
|
|
|
|
|
|
|
|
|
|
| PF-06843195 |
|
|
|
|
|
|
|
|
|
|
|
98.12% |
| PF-376304 |
|
|
|
|
|
|
|
|
|
|
|
|
| PF-4989216 |
|
|
|
|
|
|
|
|
|
|
|
99.38% |
| PH14 |
|
|
|
|
|
|
|
|
|
|
|
99.29% |
| Physalin A |
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| PI(3,4)P2 (18:1) ammonium salt |
|
|
|
|
|
|
|
|
|
|
|
|
| PI-103 |
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| PI-103 Hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
98.06% |
| PI-3065 |
|
|
|
|
|
|
|
|
|
|
|
98.97% |
| PI-540 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI-828 |
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| PI3K-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
99.46% |
| PI3K-IN-10 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-11 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-12 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-19 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| PI3K-IN-22 |
|
|
|
|
|
|
|
|
|
|
|
99.50% |
| PI3K-IN-23 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-26 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-27 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-28 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-29 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-30 |
|
|
|
|
|
|
|
|
|
|
|
98.19% |
| PI3K-IN-31 |
|
|
|
|
|
|
|
|
|
|
|
99.33% |
| PI3K-IN-32 |
|
|
|
|
|
|
|
|
|
|
|
99.7% |
| PI3K-IN-33 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-34 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-35 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-36 |
|
|
|
|
|
|
|
|
|
|
|
98.76% |
| PI3K-IN-37 |
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| PI3K-IN-38 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-41 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-46 |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| PI3K-IN-47 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-48 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-49 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-50 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-51 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-52 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-54 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-55 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-56 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-57 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-58 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-59 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-60 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-63 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K-IN-9 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/AKT-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| PI3K/AKT-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
98.10% |
| PI3K/AKT-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/AKT-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/AKT-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/AKT-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/Akt/CREB activator 1 |
|
|
|
|
|
|
|
|
|
|
|
98.64% |
| PI3K/AKT/ERK/CREB activator 1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/Akt/mTOR-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| PI3K/Akt/mTOR-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/Akt/mTOR-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/Akt/mTOR-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/Akt/mTOR-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/HDAC-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/HDAC-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/HDAC-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/HDAC-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/mTOR Inhibitor-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/mTOR Inhibitor-11 |
|
|
|
|
|
|
|
|
|
|
|
99.65% |
| PI3K/mTOR Inhibitor-12 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/mTOR Inhibitor-13 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/mTOR Inhibitor-13 sodium |
|
|
|
|
|
|
|
|
|
|
|
98.11% |
| PI3K/mTOR Inhibitor-14 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/mTOR Inhibitor-17 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/mTOR Inhibitor-2 |
|
|
|
|
|
|
|
|
|
|
|
99.10% |
| PI3K/mTOR Inhibitor-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/mTOR Inhibitor-4 |
|
|
|
|
|
|
|
|
|
|
|
97.04% |
| PI3K/mTOR Inhibitor-5 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/mTOR Inhibitor-6 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/mTOR Inhibitor-7 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/mTOR Inhibitor-8 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/mTOR Inhibitor-9 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/mTOR ligand-1 |
|
|
|
|
|
|
|
|
|
|
|
97.28% |
| PI3K/mTOR-IN-17 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/mTOR-IN-18 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/mTOR-IN-19 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/mTOR-IN-20 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/mTOR-IN-21 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/mTOR-IN-22 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/mTOR-IN-23 |
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| PI3K/mTOR-IN-23 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| PI3K/PIKK-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/PIKK-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/VEGFR2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3KC2γ-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kdelta inhibitor 1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα Ligand-1 |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| PI3Kα-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-11 |
|
|
|
|
|
|
|
|
|
|
|
95.35% |
| PI3Kα-IN-12 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-13 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-14 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-15 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-16 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-17 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-19 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-20 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-21 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-22 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-23 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-24 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-25 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-26 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-27 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-28 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-29 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-30 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-31 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-32 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-33 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
99.76% |
| PI3Kα-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα-IN-9 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα/HDAC6-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kα/mTOR-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
99.30% |
| PI3Kβ-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kγ inhibitor 1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kγ inhibitor 2 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kγ inhibitor 4 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kγ inhibitor 5 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kγ inhibitor 6 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kγ inhibitor 7 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kγ inhibitor AZ2 |
|
|
|
|
|
|
|
|
|
|
|
99.25% |
| PI3Kγ ligand 1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3kδ inhibitor 1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| PI3Kδ-IN-10 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ-IN-11 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ-IN-12 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ-IN-13 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ-IN-14 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ-IN-15 |
|
|
|
|
|
|
|
|
|
|
|
99.52% |
| PI3Kδ-IN-16 |
|
|
|
|
|
|
|
|
|
|
|
99.02% |
| PI3Kδ-IN-17 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ-IN-18 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ-IN-20 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ-IN-21 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ-IN-22 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ-IN-23 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ-IN-24 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ-IN-25 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ-IN-26 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ-IN-27 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ-IN-28 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| PI3Kδ-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ-IN-9 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ/BET-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ/HDAC6-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ/γ-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
99.39% |
| PI3Kδ/γ-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ/γ-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI4K-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
98.59% |
| PI4K-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI4KIII beta inhibitor 4 |
|
|
|
|
|
|
|
|
|
|
|
|
| PI4KIIIbeta-IN-10 |
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| PI4KIIIbeta-IN-9 |
|
|
|
|
|
|
|
|
|
|
|
99.18% |
| Pichromene |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Pictilisib |
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| Pictilisib dimethanesulfonate |
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| PIK-108 |
|
|
|
|
|
|
|
|
|
|
|
99.05% |
| PIK-124 |
|
|
|
|
|
|
|
|
|
|
|
|
| PIK-293 |
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| PIK-294 |
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| PIK-75 |
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| PIK-75 (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
| PIK-75 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| PIK-90 |
|
|
|
|
|
|
|
|
|
|
|
99.31% |
| PIK-93 |
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| PIK-C98 |
|
|
|
|
|
|
|
|
|
|
|
|
| PIK3CG Recombinant Human Active Lipid Kinase |
|
|
|
|
|
|
|
|
|
|
|
|
| Pilaralisib |
|
|
|
|
|
|
|
|
|
|
|
98.81% |
| Pilaralisib analogue |
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| PIP5K1A Recombinant Human Active Lipid Kinase |
|
|
|
|
|
|
|
|
|
|
|
|
| Pipoxolan |
|
|
|
|
|
|
|
|
|
|
|
|
| PIT-1 |
|
|
|
|
|
|
|
|
|
|
|
98.08% |
| PITCOIN4 |
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| PKI-179 |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| PKI-179 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| PKI-402 |
|
|
|
|
|
|
|
|
|
|
|
99.17% |
| PKi-402 (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
| PKN3-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
98.97% |
| PLAGL2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PP30 |
|
|
|
|
|
|
|
|
|
|
|
98.01% |
| PP487 |
|
|
|
|
|
|
|
|
|
|
|
|
| PPM-18 |
|
|
|
|
|
|
|
|
|
|
|
99.17% |
| PQR514 |
|
|
|
|
|
|
|
|
|
|
|
97.73% |
| PQR530 |
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| PQR530 (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC HIF-1α degrader-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC PI3K/110β degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC PI3K/110β degrader-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC PI3Kα degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
99.21% |
| PROTAC PI3Kα/δ degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC PI3Kδ degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| Protectin D1 |
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| PRT543 |
|
|
|
|
|
|
|
|
|
|
|
|
| PtdIns-(4,5)-P2-biotin trisodium |
|
|
|
|
|
|
|
|
|
|
|
|
| PWT-33597 |
|
|
|
|
|
|
|
|
|
|
|
|
| PWT-33597 free base |
|
|
|
|
|
|
|
|
|
|
|
|
| PX-866-17OH |
|
|
|
|
|
|
|
|
|
|
|
|
| Quercetin |
|
|
|
|
|
|
|
|
|
|
|
|
| Quercetin-d3 hydrate |
|
|
|
|
|
|
|
|
|
|
|
96.44% |
| Rafutrombopag |
|
|
|
|
|
|
|
|
|
|
|
95.29% |
| Ramentaceone |
|
|
|
|
|
|
|
|
|
|
|
|
| Recilisib |
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Recilisib sodium |
|
|
|
|
|
|
|
|
|
|
|
|
| Rhodiolin |
|
|
|
|
|
|
|
|
|
|
|
98% |
| RLX |
|
|
|
|
|
|
|
|
|
|
|
|
| RLX hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| RMC-4998 |
|
|
|
|
|
|
|
|
|
|
|
99.31% |
| RMC-4998 formic |
|
|
|
|
|
|
|
|
|
|
|
|
| RMC-4998 TFA |
|
|
|
|
|
|
|
|
|
|
|
99.02% |
| ROCK2-IN-13 |
|
|
|
|
|
|
|
|
|
|
|
|
| Roginolisib |
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| Roginolisib hemifumarate |
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| RV-1729 |
|
|
|
|
|
|
|
|
|
|
|
|
| Samotolisib |
|
|
|
|
|
|
|
|
|
|
|
98.85% |
| SAR-260301 |
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| SAR125844 |
|
|
|
|
|
|
|
|
|
|
|
98.17% |
| SAR405 |
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| SAR405 R enantiomer |
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| SB02024 |
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| Schisanhenol B |
|
|
|
|
|
|
|
|
|
|
|
|
| Schisantherin B |
|
|
|
|
|
|
|
|
|
|
|
99.75% |
| Scoulerine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| Seletalisib |
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Serabelisib |
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| SF1126 |
|
|
|
|
|
|
|
|
|
|
|
|
| SF2523 |
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| SH-273 |
|
|
|
|
|
|
|
|
|
|
|
|
| SH543 |
|
|
|
|
|
|
|
|
|
|
|
|
| Shinpterocarpin |
|
|
|
|
|
|
|
|
|
|
|
|
| SHP2-IN-35 |
|
|
|
|
|
|
|
|
|
|
|
|
| SIBP-03 |
|
|
|
|
|
|
|
|
|
|
|
|
| Sincalide |
|
|
|
|
|
|
|
|
|
|
|
99.30% |
| Sincalide ammonium |
|
|
|
|
|
|
|
|
|
|
|
99.21% |
| SJY26 |
|
|
|
|
|
|
|
|
|
|
|
|
| SKI V |
|
|
|
|
|
|
|
|
|
|
|
98.95% |
| SN32976 |
|
|
|
|
|
|
|
|
|
|
|
99.49% |
| Solenopsin |
|
|
|
|
|
|
|
|
|
|
|
|
| Sonolisib |
|
|
|
|
|
|
|
|
|
|
|
98.36% |
| SP6 |
|
|
|
|
|
|
|
|
|
|
|
|
| SPR519 |
|
|
|
|
|
|
|
|
|
|
|
|
| SQLE-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
99.21% |
| SR-3-65 |
|
|
|
|
|
|
|
|
|
|
|
|
| SRX3177 |
|
|
|
|
|
|
|
|
|
|
|
99.33% |
| SRX3207 |
|
|
|
|
|
|
|
|
|
|
|
98.36% |
| SRX3212 |
|
|
|
|
|
|
|
|
|
|
|
|
| SRX3305 |
|
|
|
|
|
|
|
|
|
|
|
|
| ST-162 |
|
|
|
|
|
|
|
|
|
|
|
|
| ST-168 |
|
|
|
|
|
|
|
|
|
|
|
|
| Strictinin |
|
|
|
|
|
|
|
|
|
|
|
97.15% |
| Strictosamide |
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| SU-11752 |
|
|
|
|
|
|
|
|
|
|
|
|
| SY-LB-35 |
|
|
|
|
|
|
|
|
|
|
|
99.54% |
| T133 |
|
|
|
|
|
|
|
|
|
|
|
|
| T3 Peptide |
|
|
|
|
|
|
|
|
|
|
|
|
| Taselisib |
|
|
|
|
|
|
|
|
|
|
|
99.75% |
| TASP0415914 |
|
|
|
|
|
|
|
|
|
|
|
99.02% |
| Taurolithocholic acid |
|
|
|
|
|
|
|
|
|
|
|
98.38% |
| Taurolithocholic acid sodium salt |
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Taurolithocholic acid-d4 |
|
|
|
|
|
|
|
|
|
|
|
98.36% |
| Taurolithocholic acid-d4 sodium |
|
|
|
|
|
|
|
|
|
|
|
99.4% |
| Taurolithocholic acid-d4-1 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
| Taurolithocholic acid-d5 |
|
|
|
|
|
|
|
|
|
|
|
|
| Taurolithocholic Acid-d5 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
| Taxamairin B |
|
|
|
|
|
|
|
|
|
|
|
|
| Tegafur-gimeracil-oteracil potassium |
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Tenalisib |
|
|
|
|
|
|
|
|
|
|
|
98.13% |
| Tenalisib R Enantiomer |
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| Tersolisib |
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| TG 100713 |
|
|
|
|
|
|
|
|
|
|
|
99.21% |
| TG100-115 |
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| TGX-115 |
|
|
|
|
|
|
|
|
|
|
|
99.31% |
| TGX-155 |
|
|
|
|
|
|
|
|
|
|
|
|
| TGX-221 |
|
|
|
|
|
|
|
|
|
|
|
99.45% |
| Tianeptine-d6 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| Topo I/II-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
| Topoisomerase I/II inhibitor 3 |
|
|
|
|
|
|
|
|
|
|
|
|
| Toyaburgine |
|
|
|
|
|
|
|
|
|
|
|
|
| trans-Isoferulic acid |
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Trilinolein |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Trilinolein-13C54 |
|
|
|
|
|
|
|
|
|
|
|
|
| Trilinolein-d5 |
|
|
|
|
|
|
|
|
|
|
|
|
| Triphenyl phosphate-d15 |
|
|
|
|
|
|
|
|
|
|
|
99.55% |
| TRK-IN-30 |
|
|
|
|
|
|
|
|
|
|
|
|
| TRPM7-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
98.83% |
| TS-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
| Tubulin-IN-55 |
|
|
|
|
|
|
|
|
|
|
|
|
| TYM-3-98 |
|
|
|
|
|
|
|
|
|
|
|
99.56% |
| UCL-TRO-1938 |
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| ULK1/2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| Umbralisib |
|
|
|
|
|
|
|
|
|
|
|
98.94% |
| Umbralisib hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.04% |
| Umbralisib R-enantiomer |
|
|
|
|
|
|
|
|
|
|
|
99.52% |
| Umbralisib sulfate |
|
|
|
|
|
|
|
|
|
|
|
|
| Umbralisib tosylate |
|
|
|
|
|
|
|
|
|
|
|
|
| Umckalin |
|
|
|
|
|
|
|
|
|
|
|
|
| UNC1062 |
|
|
|
|
|
|
|
|
|
|
|
98.92% |
| Vasculotide |
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| Vasculotide TFA |
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| VEGFR-2-IN-77 |
|
|
|
|
|
|
|
|
|
|
|
|
| VJDT |
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| Voxtalisib |
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| Vps34-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Vps34-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
99.73% |
| Vps34-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
| Vps34-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
98.79% |
| Vps34-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
| Vps34-PIK-III |
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| VS-5584 |
|
|
|
|
|
|
|
|
|
|
|
98.71% |
| Vulolisib |
|
|
|
|
|
|
|
|
|
|
|
99.61% |
| VVD-442 |
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| VVD-484 |
|
|
|
|
|
|
|
|
|
|
|
|
| VVD-699 |
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| VVD-844 |
|
|
|
|
|
|
|
|
|
|
|
|
| VVD-849 |
|
|
|
|
|
|
|
|
|
|
|
99.76% |
| WCY-8-67 |
|
|
|
|
|
|
|
|
|
|
|
|
| WCY-8-67 TFA |
|
|
|
|
|
|
|
|
|
|
|
99.40% |
| WH23 |
|
|
|
|
|
|
|
|
|
|
|
|
| WJD008 |
|
|
|
|
|
|
|
|
|
|
|
|
| WK88-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| WNY1613 |
|
|
|
|
|
|
|
|
|
|
|
|
| WS6 |
|
|
|
|
|
|
|
|
|
|
|
99.09% |
| WXM-1-170 |
|
|
|
|
|
|
|
|
|
|
|
|
| WYE-687 |
|
|
|
|
|
|
|
|
|
|
|
98.05% |
| WYE-687 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| X-370 |
|
|
|
|
|
|
|
|
|
|
|
|
| XJTU-L453 |
|
|
|
|
|
|
|
|
|
|
|
|
| YH-306 |
|
|
|
|
|
|
|
|
|
|
|
98.34% |
| YM-201636 |
|
|
|
|
|
|
|
|
|
|
|
98.07% |
| YS-49 |
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| YS-49 monohydrate |
|
|
|
|
|
|
|
|
|
|
|
99.71% |
| YVPGP |
|
|
|
|
|
|
|
|
|
|
|
|
| Zandelisib |
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| Zandelisib hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| ZINC-1000507824 |
|
|
|
|
|
|
|
|
|
|
|
|
| Zovegalisib |
|
|
|
|
|
|
|
|
|
|
|
98.80% |
| ZSTK474 |
|
|
|
|
|
|
|
|
|
|
|
99.71% |
| α-D-Manp(3→1)-α-D-Manp(2→1)-α-D-Glu |
|
|
|
|
|
|
|
|
|
|
|
|
| α-Linolenic acid sodium |
|
|
|
|
|
|
|
|
|
|
|
96.66% |
| α-Linolenic acid |
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| α-Linolenic acid (Standard) |
|
|
|
|
|
|
|
|
|
|
|
99.32% |
| α-Linolenic acid-13C18 |
|
|
|
|
|
|
|
|
|
|
|
99.5% |
| α-Linolenic acid-d14 |
|
|
|
|
|
|
|
|
|
|
|
|
| α-Linolenic acid-d5 |
|
|
|
|
|
|
|
|
|
|
|
97.80% |
| Gamma-glutamylcysteine |
|
|
|
|
|
|
|
|
|
|
|
98.53% |
| Gamma-glutamylcysteine TFA |
|
|
|
|
|
|
|
|
|
|
|
96.68% |
| Notoginsenoside Ft1 |
|
|
|
|
|
|
|
|
|
|
|
99.49% |
| Sericin |
|
|
|
|
|
|
|
|
|
|
|
0% |
| Salvianolic acid F |
|
|
|
|
|
|
|
|
|
|
|
99.30% |
| Ethalfluralin |
|
|
|
|
|
|
|
|
|
|
|
|
| Dihydrocapsaicin-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
| Dihydrocapsaicin |
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Quercetin dihydrate |
|
|
|
|
|
|
|
|
|
|
|
96.0% |
| Ginsenoside Rk1 |
|
|
|
|
|
|
|
|
|
|
|
99.37% |
| High density lipoprotein (human) |
|
|
|
|
|
|
|
|
|
|
|
|
| Bacopaside I |
|
|
|
|
|
|
|
|
|
|
|
99.20% |
| Clifutinib |
|
|
|
|
|
|
|
|
|
|
|
99.59% |
| Ponicidin |
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Ononin |
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| Heptadecanoic acid |
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Flavokawain A |
|
|
|
|
|
|
|
|
|
|
|
99.73% |
| Flavokawain C |
|
|
|
|
|
|
|
|
|
|
|
99.53% |
| Deoxyandrographolide |
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Deoxyshikonin |
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| 1-Deoxynojirimycin hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| 4,4'-Sulfonyldiphenol |
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| Tianeptine-d12 |
|
|
|
|
|
|
|
|
|
|
|
|
| Tianeptine |
|
|
|
|
|
|
|
|
|
|
|
99.21% |
| Tianeptine sodium salt |
|
|
|
|
|
|
|
|
|
|
|
99.71% |
| Tioconazole |
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Momordin Ic |
|
|
|
|
|
|
|
|
|
|
|
99.78% |
| Kukoamine B |
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| Kukoamine B-d5 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| Kukoamine B mesylate |
|
|
|
|
|
|
|
|
|
|
|
|
| Doxepin |
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| Doxycycline-d3 (hyclate) (major) |
|
|
|
|
|
|
|
|
|
|
|
|
| Heterophyllin B |
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Benzoin |
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Benzoin-d10 |
|
|
|
|
|
|
|
|
|
|
|
|
| Propylparaben sodium |
|
|
|
|
|
|
|
|
|
|
|
99.03% |
| Propylparaben-d4 |
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| Propylparaben-d7 |
|
|
|
|
|
|
|
|
|
|
|
|
| Kaempferide |
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Hawthorn Extract |
|
|
|
|
|
|
|
|
|
|
|
|
| Arnicolide D |
|
|
|
|
|
|
|
|
|
|
|
99.69% |
| Levomilnacipran hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Levomilnacipran-d5 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| Levalbuterol hemitartrate |
|
|
|
|
|
|
|
|
|
|
|
98.71% |
| Buparlisib |
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| Buparlisib Hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| Copanlisib |
|
|
|
|
|
|
|
|
|
|
|
99.35% |
| Copanlisib dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
99.55% |
| Isorhapontigenin |
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| Isoviolanthin |
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| Isoacteoside |
|
|
|
|
|
|
|
|
|
|
|
99.73% |
| Isoastragaloside I |
|
|
|
|
|
|
|
|
|
|
|
99.49% |
| Isorhamnetin |
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| Isorhamnetin (Standard) |
|
|
|
|
|
|
|
|
|
|
|
98% |
| Dinitramine |
|
|
|
|
|
|
|
|
|
|
|
|
| Neoandrographolide |
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| Epimedin A |
|
|
|
|
|
|
|
|
|
|
|
99.43% |
| Oroxin B |
|
|
|
|
|
|
|
|
|
|
|
99.39% |
| Micheliolide |
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| Fenitrothion |
|
|
|
|
|
|
|
|
|
|
|
99.43% |
| Myricetin |
|
|
|
|
|
|
|
|
|
|
|
98.68% |
| Pinoresinol Diglucoside |
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| Pectolinarigenin |
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| Phlorizin |
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Phlorizin dihydrate |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| (±)-Myrtenol |
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| Kuwanon G |
|
|
|
|
|
|
|
|
|
|
|
99.45% |
| (+)-Medioresinol |
|
|
|
|
|
|
|
|
|
|
|
99.13% |
| Sophocarpine |
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Sophocarpine monohydrate |
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Quercetin-13C3 |
|
|
|
|
|
|
|
|
|
|
|
|
| Quercetin-d3 |
|
|
|
|
|
|
|
|
|
|
|
98.73% |
| Quercetin-d5 |
|
|
|
|
|
|
|
|
|
|
|
|
| Quercetin |
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Quercetin hydrate |
|
|
|
|
|
|
|
|
|
|
|
98.45% |
| Picolinafen |
|
|
|
|
|
|
|
|
|
|
|
|
| Flupentixol |
|
|
|
|
|
|
|
|
|
|
|
|
| Nickel(II) oxide |
|
|
|
|
|
|
|
|
|
|
|
|
| Lanthanum(Ⅲ) chloride |
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Doxycycline monohydrate |
|
|
|
|
|
|
|
|
|
|
|
98.95% |
| Tabersonine |
|
|
|
|
|
|
|
|
|
|
|
98.02% |
| Tabersonine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
98.55% |
| Arenobufagin |
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| Alisol B acetate |
|
|
|
|
|
|
|
|
|
|
|
|
| Rafutrombopag (tautomerism) |
|
|
|
|
|
|
|
|
|
|
|
98.33% |
| Wortmannin |
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Ganoderic acid DM |
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| Gallein |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Vitexin-2"-O-rhamnoside |
|
|
|
|
|
|
|
|
|
|
|
99.78% |
| Phellopterin |
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Rigosertib |
|
|
|
|
|
|
|
|
|
|
|
98.17% |
| Rigosertib sodium |
|
|
|
|
|
|
|
|
|
|
|
99.57% |
| Polygalasaponin F |
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Licoricesaponin G2 |
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| Sorafenib tosylate |
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| Beauvericin |
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| Ginkgolic Acid (C13:0) |
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Astringin |
|
|
|
|
|
|
|
|
|
|
|
98.97% |
| Thymoquinone |
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Vasicine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
98.62% |
| Doxycycline-d3 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
| Flupentixol dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
98.52% |
| Phellodendrine chloride |
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| Berberine hemisulfate |
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| Triphenyl phosphate |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Esculetin |
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Raddeanin A |
|
|
|
|
|
|
|
|
|
|
|
98.68% |
| Sorafenib |
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| Hydroxy celecoxib |
|
|
|
|
|
|
|
|
|
|
|
98.71% |
| Propylparaben |
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Voacamine |
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| Poly-L-ornithine hydrobromide (MW 5000-15000) |
|
|
|
|
|
|
|
|
|
|
|
|
| Cholesta-3,5-diene |
|
|
|
|
|
|
|
|
|
|
|
99.54% |
| Lipoteichoic acid |
|
|
|
|
|
|
|
|
|
|
|
|
| Idelalisib-d5 |
|
|
|
|
|
|
|
|
|
|
|
98.35% |
| Idelalisib |
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Erucic acid |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Erucic acid-d18-1 |
|
|
|
|
|
|
|
|
|
|
|
|
| Sotetsuflavone |
|
|
|
|
|
|
|
|
|
|
|
|
| Alizarin |
|
|
|
|
|
|
|
|
|
|
|
99.48% |
| Skimmianine |
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Androsin |
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Curzerenone |
|
|
|
|
|
|
|
|
|
|
|
98.55% |
| Liensinine |
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| Liensinine Diperchlorate |
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Fusaric acid |
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Glaucocalyxin A |
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Cranberry Extract |
|
|
|
|
|
|
|
|
|
|
|
|
| Bakkenolide A |
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Resibufogenin |
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Dracorhodin perchlorate |
|
|
|
|
|
|
|
|
|
|
|
99.02% |
| Sipeimine |
|
|
|
|
|
|
|
|
|
|
|
98.57% |
| Plantamajoside |
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Telocinobufagin |
|
|
|
|
|
|
|
|
|
|
|
99.50% |
| Polygalacin D3 |
|
|
|
|
|
|
|
|
|
|
|
|
| Hyaluronic acid-BSA |
|
|
|
|
|
|
|
|
|
|
|
|
| Hyaluronic acid |
|
|
|
|
|
|
|
|
|
|
|
|
| Hyaluronic acid sodium |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Tenacissoside H |
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Jujuboside B |
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Physalin B |
|
|
|
|
|
|
|
|
|
|
|
97.20% |
| Euscaphic acid |
|
|
|
|
|
|
|
|
|
|
|
98.14% |
| Scoulerine |
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Rotundic acid |
|
|
|
|
|
|
|
|
|
|
|
98.41% |
| Psicose |
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Hederacolchiside A1 |
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Citronellol |
|
|
|
|
|
|
|
|
|
|
|
98.40% |
| Citronellol-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
| Typhaneoside |
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| Lumretuzumab |
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Vasicine |
|
|
|
|
|
|
|
|
|
|
|
98.80% |
| Flavokawain B |
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Phellodendrine |
|
|
|
|
|
|
|
|
|
|
|
|
| Coptisine |
|
|
|
|
|
|
|
|
|
|
|
|
| Coptisine Sulfate |
|
|
|
|
|
|
|
|
|
|
|
99.37% |
| Berberine |
|
|
|
|
|
|
|
|
|
|
|
|
| Berberine sulfate |
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| Veratramine |
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Sinigrin |
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Sinigrin hydrate |
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Bellidifolin |
|
|
|
|
|
|
|
|
|
|
|
99.74% |